Methylcobalamin (Active B12): What It Is, Where to Get It Prescribed, and What It Costs

Vitamin B12, or cobalamin, is a large molecule built around a single cobalt atom. The group attached on top of that cobalt — the "upper ligand" — is what distinguishes the forms on labels: cyanocobalamin carries a cyanide group, hydroxocobalamin a hydroxyl group, methylcobalamin a methyl group. Inside the cell only two forms do any work: methylcobalamin, the cofactor for methionine synthase, and adenosylcobalamin, the cofactor for methylmalonyl-CoA mutase. Every other form is converted into one of those two first.

That is why methylcobalamin is called "active" or "coenzyme" B12. It is a description of chemistry, not a claim about how well it works once injected — a distinction that runs through this whole page.

Humans cannot make B12. Bacteria synthesise it, animal foods concentrate it, and the liver keeps a reserve that typically lasts years. The methylcobalamin in a pharmacy vial is a purified synthetic version of the same molecule found in food and in your own tissues. "Vitamin B12" on a supplement label almost always means cyanocobalamin — a stable, inexpensive form that does not occur in nature but is easily converted by the body. Methylcobalamin is sold as "mecobalamin" in Japan, where it has been a prescription drug for decades.

It is not a stimulant, and there is no mechanism by which it would make a person with adequate B12 feel more energetic. It is not a weight-loss drug, although it appears in weight-management injections such as Lipo-B as a B-vitamin component. And it is not a treatment for nerve pain of any cause — the neurological literature concerns nerves damaged by B12 deficiency.

Methylcobalamin is the cofactor that lets methionine synthase convert homocysteine back into methionine. Methionine becomes S-adenosylmethionine, the body's main methyl donor for DNA, neurotransmitters, membrane phospholipids and myelin. When B12 is short, homocysteine accumulates; an elevated level is one of the markers physicians use to confirm a functional deficiency.

The other active form, adenosylcobalamin, handles a separate mitochondrial reaction, converting methylmalonyl-CoA to succinyl-CoA. When B12 is deficient, methylmalonic acid builds up, and it is the most specific blood marker of true deficiency. Injected methylcobalamin supplies this pathway too, because cells strip the upper ligand off whatever form arrives and rebuild both coenzymes from the core molecule.

Without working methionine synthase, folate gets stuck in a form the cell cannot use for DNA synthesis. Rapidly dividing cells — bone marrow above all — suffer first, which is why B12 deficiency produces large, immature red cells (megaloblastic anaemia). It is also why folic acid given alone to a B12-deficient person can improve the blood count while nerve damage continues.

The methylation cycle maintains myelin, the insulating layer around nerve fibres. Deficiency produces a recognisable pattern: numbness and tingling in the hands and feet, loss of position sense, unsteady gait, in advanced cases damage to the spinal cord (subacute combined degeneration), and mood and memory changes. The New England Journal of Medicine review from 2013 and the Nature Reviews Disease Primers review from 2017 both stress that neurological symptoms can appear before, or entirely without, any change in the blood count.

Oral B12 needs stomach acid to free it from food, intrinsic factor from the stomach lining to carry it, and a healthy terminal ileum to absorb it. Pernicious anaemia (autoimmune loss of intrinsic factor), stomach or bowel surgery, Crohn's disease, long-term acid suppression and metformin all interfere. An intramuscular injection enters the blood regardless of what the gut is doing. That is the actual reason injections exist — not because injected B12 is stronger.

This is where the evidence is definitive. Correcting B12 deficiency corrects megaloblastic anaemia, lowers methylmalonic acid and homocysteine, and improves or halts the neurological picture, with the degree of nerve recovery depending on how long the damage has been present. The British Society for Haematology guideline (British Journal of Haematology, 2014) and the Mayo Clinic Proceedings review "The Many Faces of Cobalamin Deficiency" (2019) cover diagnosis and management in detail. Deficiency is common among vegetarians and especially vegans (Nutrition Reviews, 2013; European Journal of Clinical Nutrition, 2014), in long-term metformin users (Diabetes Prevention Program Outcomes Study, Journal of Clinical Endocrinology & Metabolism, 2016), in older adults, after gastric or bowel surgery, and with long-term acid suppression.

Two Cochrane reviews (2005, updated 2018) examined the randomised trials comparing oral with intramuscular B12 for deficiency. The 2018 update found three trials with 153 participants and concluded, on low-quality evidence, that oral and intramuscular B12 had similar effects on serum levels. The best-known single trial, in Blood in 1998, randomised 38 newly diagnosed deficient patients to 2 mg oral daily or a standard intramuscular schedule and reported that correction of blood and neurological abnormalities was prompt and indistinguishable.

The honest reading: for many deficient people, high-dose oral B12 works. Injections are the clear choice when absorption is unreliable, when neurological symptoms make rapid repletion the priority, or when tablets have not worked.

The question most people arrive with — is methylcobalamin better than cyanocobalamin? — has been examined directly. A 2015 review in Molecular Nutrition & Food Research concluded that the coenzyme forms "are not likely to be superior" to cyano- or hydroxocobalamin for preventing or treating deficiency, because cells remove the upper ligand from every form and rebuild the coenzymes themselves. What can honestly be said for methylcobalamin is narrower: it carries no cyanide group (trivial for almost everyone, though cyanocobalamin is avoided in the rare inherited optic neuropathy called Leber's disease), and some patients and prescribers prefer it on that basis.

Methylcobalamin has been studied in diabetic peripheral neuropathy, mostly in small trials from Asia, often alongside another treatment. A 2026 review and meta-analysis in the Journal of Clinical Medicine pooled thirteen randomised trials of B-vitamin supplementation (834 participants) and reported small improvements in some neuropathy scores and in sural nerve conduction, no significant effect on pain by standard scales, and enough heterogeneity and risk of bias that the authors declined to recommend routine use. Diabetes guidelines do not list B12 as a neuropathy treatment for people who are not deficient.

This is the claim worth being most careful about. B12 injections are widely marketed for energy, and the biochemistry gives a plausible story: no B12, no methylation, tired cells. But the story only holds if B12 is actually short. In people with normal levels there is no convincing trial evidence that injected B12 improves energy, mood or exercise capacity. The closest thing to a direct test — a small pilot study of B12 for tiredness in the British Journal of Nutrition in 1973 — is half a century old and has never been followed by a properly powered trial showing benefit. People who feel better after an injection when their levels were fine are most likely describing expectation, or a borderline deficiency that had gone undetected.

A great deal, and it points one way. Randomised trials and decades of practice establish that B12 replacement — oral or injected, any common form — corrects deficiency and its consequences. What the human data does not do is support B12 as a general tonic. No randomised trial shows methylcobalamin injections improve energy, cognition or performance in people with normal B12 status, and none shows methylcobalamin outperforming cyanocobalamin on any clinical outcome.

• That methylcobalamin is clinically superior to cyanocobalamin or hydroxocobalamin. The review literature argues the opposite.
• Any benefit for energy, fatigue or cognition in people whose B12 status is normal.
• B12 as a treatment for neuropathy not caused by B12 deficiency.
• A weight-loss effect, even when B12 appears in weight-management injections.

If you were deficient, this is when the blood picture starts to respond: the marrow begins producing normal red cells within days and reticulocytes rise within about a week. Some people describe feeling better in this window; others notice nothing yet. If you were not deficient, the vitamin is stored or excreted and there is no expected change.

In deficiency, haemoglobin recovers over several weeks and methylmalonic acid and homocysteine normalise. Fatigue caused by anaemia lifts as the blood count does. Numbness and tingling, when caused by deficiency, begin to improve here but move more slowly than the blood.

Nerve recovery is the slow part. The neurological literature describes improvement continuing for six months or longer, and warns that damage present for more than a year may only partially recover — which is why physicians treat neurological deficiency promptly.

Pernicious anaemia, a gastrectomy, a bypass, a strictly plant-based diet or long-term metformin do not go away. In those cases B12 is maintenance rather than a course, and the weekly injection may move to a less frequent schedule once stores are rebuilt. Your physician decides that from your levels, not the calendar.

The directions are written in millilitres and in insulin-syringe units because that is what you can read off the barrel. 1.25 mL is 125 units on a U-100 syringe. At the vial's concentration of 2 mg/mL, that volume is 2.5 mg of methylcobalamin per injection. You are not calculating anything — the number is printed on your medication and your physician sets it.

Unlike most products on this site, methylcobalamin is directed intramuscularly — into the muscle, not the fat layer under the skin. The usual sites are the outer thigh and the upper outer buttock. Intramuscular injection uses a longer needle than a subcutaneous one, and your pharmacy supplies syringes and needles appropriate to the directions. Rotate sites between weeks. A brief sting and a slightly sore site the next day are normal. Do not change the route your physician prescribed; if it is a problem for you, raise it with them.

Four doses at once weekly is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always — not a stockpile.

Methylcobalamin is light-sensitive: keep the vial in its carton, out of direct light, at the temperature printed on the label. The beyond-use date is on the label; a multi-dose vial is discarded after that date regardless of how much is left.

Same vitamin, different upper ligand, different regulatory status. Cyanocobalamin injection is FDA approved, inexpensive and the standard in US practice; the body converts it to the coenzyme forms. Methylcobalamin arrives already in one, but cells strip and rebuild the ligand regardless, and the review literature does not find it clinically superior. Reasons a physician might choose methylcobalamin: avoiding the cyanide group, a patient with Leber's hereditary optic neuropathy, or patient preference. Reasons to choose cyanocobalamin: it is the approved product with the longest track record. Neither is wrong.

For deficiency without a serious absorption problem, the Cochrane evidence says high-dose oral B12 works about as well as injections. Injections win when absorption is the problem — pernicious anaemia, bowel surgery, gastric bypass — or when neurological symptoms make rapid repletion the priority.

Lipo-B is B12 plus methionine, inositol and choline, prescribed as part of a weight-management plan rather than for B12 replacement. If the aim is to correct or maintain B12 status, methylcobalamin alone is the more direct tool; if the aim is a supporting injection alongside a weight plan, Lipo-B is what that product is for.